# Metoclopramide Test in Hyperprolactinemic Women With Polycystic Ovarian Syndrome: Old Wine Into New Bottles?

Claire Rodier, Blandine Courbiere, Sara Fernandes, Marie Vermalle, Bretelle

Florence, Noemie Resseguier, Thierry Brue, Thomas Cuny

► To cite this version:

Claire Rodier, Blandine Courbiere, Sara Fernandes, Marie Vermalle, Bretelle Florence, et al.. Metoclopramide Test in Hyperprolactinemic Women With Polycystic Ovarian Syndrome: Old Wine Into New Bottles?. Frontiers in Endocrinology, 2022, 13, pp.832361. 10.3389/fendo.2022.832361. hal-03678845

HAL Id: hal-03678845

https://hal.science/hal-03678845

Submitted on 25 Oct 2023

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
<figure><img src="image_2.png" /></figure>

Check for
updates

# Metoclopramide Test in Hyperprolactinemic Women With Polycystic Ovarian Syndrome: Old Wine Into New Bottles?

Claire Rodier<fnref n="1" />, Blandine Courbière<fnref n="1" />,<fnref n="2" />, Sara Fernandes³,⁴, Marie Vermalle<fnref n="1" />,⁵, Bretelle Florence<fnref n="1" />, Noémie Resseguier³,⁴, Thierry Brue⁵† and Thomas Cuny⁵*†

## OPEN ACCESS

**Edited by:**

Hidenori Fukuoka,
Kobe University, Japan

**Reviewed by:**

Fumio Otsuka,
Okayama University, Japan
Antonio Aversa,
University of Catanzaro, Italy

**\*Correspondence:**

Thomas Cuny
thomas.cuny@ap-hm.fr

†These authors have contributed equally to this work and share senior authorship

**Specialty section:**

This article was submitted to Pituitary Endocrinology, a section of the journal Frontiers in Endocrinology

Received: 09 December 2021

Accepted: 14 January 2022

Published: 18 February 2022

**Citation:**
Rodier C, Courbière B, Fernandes S, Vermalle M, Florence B, Resseguier N, Brue T and Cuny T (2022) Metoclopramide Test in Hyperprolactinemic Women With Polycystic Ovarian Syndrome: Old Wine Into New Bottles? *Front. Endocrinol.* 13:832361.
doi: 10.3389/fendo.2022.832361

**Introduction:** Polycystic ovarian syndrome (PCOS) is the most frequent etiology of anovulation, hyperandrogenism and infertility in women. Its pathophysiology remains poorly elucidated. Hyperprolactinemia (hPRL) is common in women of reproductive age and may partially mimic the clinical phenotype of PCOS. The simultaneous finding of both conditions is therefore not rare, however there are conflicting studies on whether a link exists between them.

**Materials and Methods:** We conducted a retrospective monocentric study between 2015 and 2021 and among women who were referred for possible PCOS, we selected those who met the ESHRE/Rotterdam definition criteria. hPRL was defined as two values above the upper limit of normal with at least one measurement in our centre.

**Results:** A total of 430 women were selected, of whom 179 met the PCOS criteria. 50 out of 179 patients (27.9%) had at least one elevated value of PRL and 21 (11.7%) had hPRL according to our definition. Among the 21 women of the PCOS/hPRL cohort, 5 (23.8%) had a microprolactinoma and all of them had PRL level ≥ 60 ng/ml. The remaining cases were macroprolactinemia (n=5), iatrogenic hPRL (n=4), primary hypothyroidism (n=1) or unexplained (n=6) despite exhaustive investigations. The metoclopramide test resulted in an increase of basal PRL < 300% in all prolactinomas and ≥ 300% in all the other etiologies.

**Conclusion:** hPRL was a common finding in PCOS women, secondary to a microprolactinoma in a quarter of cases. Metoclopramide test performed in women with hPRL below 60 ng/ml appeared as a helpful tool 1) to discriminate pituitary causes from others etiologies, 2) to potentially avoid unnecessary pituitary MRI.

**Keywords:** PCOS, hyperprolactinemia, hyperandrogenism, oligo-anovulation, metoclopramide test

<footnote n="1">¹Department of Gynecology-Obstetric and Reproductive Medicine, AP-HM, Hôpital La Conception, Marseille, France,</footnote>

<footnote n="2">²CNRS, IRD, IMBE, Avignon Université, Aix Marseille Univ, Marseille, France, ³Aix Marseille Univ, APHM, Hôpital de la Timone, Service d'Epidemiologie et d'Economie de la Santé, Unité de Recherche Clinique, Direction de la Recherche en Santé, Marseille, France, ⁴EA3279, CEReSS, Health Service Research and Quality of Life Center, Aix-Marseille University, Marseille, France, ⁵Aix Marseille Univ, APHM, Marseille Medical Genetics, Inserm U1251 and Hôpital de la Conception, Service d'Endocrinologie, Marseille, France</footnote>
# INTRODUCTION

Polycystic ovarian syndrome (PCOS) is the most frequent etiology of anovulation, hyperandrogenism and infertility in women. Indeed, between 2.2 and 21.3% of women in reproducing age are diagnosed with this pathology (1), with up to 70% of affected women undiagnosed (2). Both oligo-anovulation and hyperandrogenism constitute the cardinal features of PCOS, while insulin resistance and excess weight largely contribute to its pathogenesis, clinical/biochemical manifestations, and long-term sequelae (3).

Despite this high rate and an extended time of study (PCOS has been described since 1935 when Irving Stein and Michael Leventhal identified an association between amenorrhea and bilateral polycystic ovaries), the pathophysiology of PCOS remains unclear. Hyperprolactinemia (hPRL), defined as an excess of prolactin in blood above laboratory reference limits, is also common in women of reproductive age and may mimic the clinical phenotype of PCOS. The prevalence of hPRL is hard to accurately assess, however it could concern up to 4% of women (4). When facing hPRL, pregnancy, breastfeeding, medications, and the presence of macroprolactinemia must be ruled out in priority. The latter results from the formation of prolactin-immunoglobulin complex, and was recognized as a frequent cause of hPRL since many years (5), with an incidence as high as 25% in some series (6). It is, however, usually asymptomatic due to the limited bioavailability and bioactivity of the macromolecule. Finally, pathological causes like hypothyroidism, renal insufficiency and pituitary adenomas (mainly prolactin-secreting phenotype, PRLomas) represent the remaining causes encountered in clinical practice. PRLomas account for as much as 60% of pituitary adenomas (7), microadenomas in young women being the most typical presentation. On the other hand, the simultaneous finding of a hPRL and PCOS is not rare, with a reported prevalence of hPRL ranging between 2 and 22% in PCOS women (8, 9). Therefore, distinguishing hPRL due to PRLomas from other causes of hPRL is relevant, as it could, in case of a PRLoma, result either in the prescription of dopamine agonist therapy, or even pituitary surgery (10). This is of upmost importance in case of infertility, where combined treatment for PCOS and hPRL are actively discussed, in order to restore menstrual cycles and a regular qualitative ovulation.

Therefore, the aim of this study was to determine the prevalence of hPRL among a large cohort of well-characterized PCOS women, and to further describe the causes of hPRL in this context.

# MATERIAL AND METHODS

## Study Design

We conducted a retrospective monocentric study of patients admitted between January 2015 and July 2021 at the University Hospital La Conception in Marseille, either in the day hospital of the Endocrinology Department or in the Medically Assisted Procreation Department. Women with clinical symptoms

suggestive of PCOS (oligo-anovulation, hyperandrogenism, menstrual irregularities, hirsutism, acne) were selected in our computer database (Figure 1). We, then, selected only women who met the diagnosis criteria of PCOS used by the European Society of Human Reproduction and Embryology (ESHRE), established in 2018 (Table 1) (11), even for women diagnosed before 2018. According to these criteria, four different phenotypes of PCOS are described: A, when the 3 PCOS criteria are met, B, for ovulatory dysfunction and hyperandrogenism, C, for hyperandrogenism and polycystic ovarian morphology, and, D, for ovulatory dysfunction and polycystic ovarian morphology. Women were respectively classified as being underweight (BMI < 18.5 kg/m²), of normal weight (18.5 ≤ BMI < 25 kg/m²), overweight (25 ≤ BMI < 30 kg/m²) or obese (BMI ≥ 30 kg/m²).

All the women enrolled in this study underwent a standardized clinical, biochemical and imaging work-up at our centre. LH, FSH, prolactin (PRL), antimullerian hormone (AMH), 17-OH-progesterone, estradiol, testosterone, delta 4 androstenedione and dehydroepiandrosterone sulfate (DHEAS) were measured in the plasma. PRL chromatography was performed to rule out macroprolactinemia or big prolactin only if the basal PRL value was elevated. Women with a single high value of PRL were systematically candidate to a second measurement or asked for a previous PRL value (Figure 1). We considered patients as being hPRL, if they had at least two

<figure><img src="image_3.png" /><figcaption>**FIGURE 1** | Flow Chart of the Study. CAH, Congenital Adrenal Hyperplasia; hPRL, hyperprolactinemia; nPRL, normoprolactinemia; PCOS, Polycystic Ovary Syndrome; PRL, Prolactin; ULN, Upper Limit of Normal.</figcaption></figure>
<table><caption>**TABLE 1** | Diagnosis criteria of PCOS used by the European Society of Human Reproduction and Embryology (ESHRE), established in the Rotterdam consensus in 2018.</caption><thead><tr><th>Criteria</th><th>Details</th></tr></thead><tbody><tr><td>Irregular cycles and ovulatory dysfunction (OD)</td><td>Irregular menstrual cycles are defined as:<ul><li>normal in the first-year post menarche</li><li>> 1 to < 3 years post menarche: < 21 or > 45 days</li><li>> 3 years post menarche: < 21 or > 35 days or < 8 cycles per year</li><li>> 1 year post menarche > 90 days for any one cycle</li></ul></td></tr><tr><td>Biochemical or clinical hyperandrogenism (HA)</td><td><ul><li>Elevated levels of testosterone, Androstenedione or dehydroepiandrosterone sulfate (DHEAS)</li><li>Acne, alopecia, hirsutism</li></ul></td></tr><tr><td>Polycystic ovarian morphology (PCOM)</td><td>At least 1 of the 2 ovaries presenting:<ul><li>>= 20 follicles using endovaginal ultrasound transducers with a frequency bandwidth that includes 8MHz</li><li>Volume>10 mL</li><li>Surface >5,5cm2</li></ul></td></tr><tr><td colspan="2">At least 2 criteria out of the 3</td></tr><tr><td colspan="2"><b>After exclusion of non-classic congenital adrenal hyperplasia, Cushing's, adrenal or ovarian virilizing tumors.</b></td></tr></tbody></table>

measurements of PRL, including one performed in our centre, above the upper limit of normal (ULN).

Women were excluded from the study in case of pregnancy, current breastfeeding, other causes of hyperandrogenism (Cushing's syndrome, classic or non-classic congenital adrenal hyperplasia), current intake of hPRL drugs (including estrogen/progestin birth control pill) or interrupted less than 4 weeks before admission to the hospital. Accordingly, we paid a careful attention that none of our patients were taken medications or even supplements known to interfere with the PRL and/or the dopamine receptor system. Systemic disease known to increase PRL (inflammatory diseases, renal insufficiency, or hypothyroidism) were also ruled out. For hypothyroidism, all the women had contemporary measurement of TSH (normal range: 0.27 - 4.2 mIU/l) and free T4 (fT4) and those with TSH above ULN were excluded from our study. Note that women with TSH above ULN had a further measurement of thyroperoxidase and thyroglobulin antibodies. Likewise, TRH dynamic test was not performed in any patient of our cohort.

The study was approved by the data protection department of Aix-Marseille University (PADS authorization number 2020-136).

## Imaging Procedures

Pelvic ultrasounds were performed by skilled radiologists, either by suprapubic or transvaginal way, and determined the number of follicles, the ovarian volume as well as the ovarian surface. The latter likely have a slightly higher diagnostic performance than ovarian volume, when using a threshold of 5.5cm2 (12). The threshold of ≥ 20 follicles in, at least, one ovary was used as a criteria of PCOS. When performed, pituitary MRI was systematically done before pituitary dynamic tests (LHRH and metoclopramide tests), and read by an expert radiologist.

## Hormonal Assessment
### Standard Hormonal Evaluation

The PRL measurement performed in the endocrine laboratory of the University hospital of Marseille used the Roche automaton COBAS 6000 e-601, which is a sandwich electrochemiluminescence immunoassay. This assay was approved by the COFRAC (French Comity of Certification) according to the norm ISO EN NF 15189

and has the following accuracy: 0.012% at 14.617 ng/ml and 1.28% at 34.169 ng/ml. For every women with a PRL value above ULN in our laboratory, another measurement was performed, or we asked for a previous value, that could have been performed in another laboratory.

For steroid hormones (estradiol, testosterone, DHEAS and 17-OH-progesterone), results are normalized as compared to ULN (because of normal ranges which differ, depending on the period of the patient's cycle or age).

Every women with a 17-OH-Progesterone ≥ ULN underwent an ACTH Stimulation test (Synacthene® 0.25 mg). If the latter confirmed possible congenital non classic adrenal hyperplasia, the patient was excluded from the analysis.

## Dynamic Hormonal Testing

### Metoclopramide Test

Metoclopramide test was performed in the outpatient facility of the endocrine department (daily hospital), to help distinguishing adenomatous from non-adenomatous causes of hPRL, as previously described (12, 13). Practically, after patient's consent, the test started by a measurement of PRL before (T0) iv administration of 10 mg of metoclopramide, followed by a measurement at 30 (T30) and 60 minutes (T60) post-injection, respectively. For the interpretation, we calculated the relative increase of PRL, as follows: (PRL peak value - PRL baseline value) x100/PRL baseline value. The response was considered negative if the increase was < 100%, weak if the increase remained < 300% and positive if the increase was ≥ 300%. In case of PRLoma, the response is usually negative or weak, whereas it is positive in other causes of hPRL (14).

### LHRH Test

All LHRH tests were performed in our daily hospital unit, after patient's consent. A baseline measurement (T0) of LH and FSH was performed, followed by an injection of 100 µg of GnRH (Gonadorelin®) and subsequent measures of at 30 (T30) and 60 minutes (T60).

We calculated the LH/FSH ratio which should be below 1, but is usually reported as being ≥ 1 in PCOS women (14). In addition, we also used the LH T30/LH T0 ratio to assess the
intensity of the LH stimulation. This ratio is likely ≥ 5 in women with PCOS (14).

## Statistics

Descriptive statistics, including the frequency and percentage for categorical variables, and the mean and standard deviation for continuous variables, were used to describe the cohort of women with PCOS.

Sociodemographic and clinical characteristics were compared between the cohort of PCOS/hPRL women and the cohort of PCOS/nPRL women, using Student's t-test or Mann-Whitney test for continuous variables, and Chi-squared test or Fisher's exact test for categorical variables when appropriate. A ROC curve was established to compare PRL threshold of interest for the etiological diagnostic of hPRL.

Spearman's rank correlation coefficient between AMH and prolactin was estimated. All tests were two-sided. A p value ≤ 0.05 was considered statistically significative. All statistical analyses were performed using the software SPSS, version 20.0 (SPSS, Inc., Chicago, Illinois).

## RESULTS

### Characteristics of PCOS Women

A total of 430 women with clinical symptoms suggestive of PCOS (oligo-anovulation, hyperandrogenism, menstrual irregularities, hirsutism, acne) were selected in our computer database (Figure 1), among whom 179 met the 2018 diagnosis criteria of PCOS. The mean age at inclusion was 23.8 ± 5.2 years and the mean body mass index (BMI) was 25.8 ± 6.1 kg/m². Based on their BMI, they were classified as underweight (n = 10, 5.6%), of normal weight (n = 85, 47.5%), overweight (n = 43, 24%) or obese (n = 41, 22.9%). Regarding PCOS phenotypes, 48% had a phenotype A, 33% phenotype B, 10.1% phenotype C, and 8.9% a phenotype D (Table 2). We did not observe a significant association between the PCOS phenotype and BMI of the patient (Figure 2, p = 0.35). In the whole cohort, 161/179 (89.9%) women had menstrual irregularities, 163/179 (91%) had either a clinical and/or biological hyperandrogenism and 120/179 (67%) had ultrasonographic criteria for PCOS. The characteristics of the whole PCOS population of patients are summarized in Table 2.

### Prolactin and PCOS

A total of 50 patients (28%) had at least one value suggesting hPRL, among whom 21 (42%) had a second measure confirming hPRL. According to our definition, the overall prevalence of hPRL in our PCOS cohort was 11.7%.

Clinical and biological features of the two populations of patients (PCOS/nPRL vs. PCOS/hPRL) are described in Table 3. Provoked galactorrhea was found in 4 PCOS/nPRL patients and not in the PCOS/hPRL group (p = 0.54). Obesity was observed in 1/21 (4.8%) PCOS/hPRL patients as compared to 40/158 (25.3%) in the PCOS/nPRL group, while mean BMI did not differ significantly between the two populations of patients

<table><caption>TABLE 2 | Description of the total cohort of the study.</caption><thead><tr><th>Characteristics</th><th>Total cohort (n = 179)</th></tr></thead><tbody><tr><td><strong>Age, y</strong></td><td></td></tr><tr><td>Mean ± SD</td><td>23.8 ± 5.2</td></tr><tr><td>Median (range)</td><td>22 (18 – 40)</td></tr><tr><td><strong>BMI, kg/m<sup>2</sup></strong></td><td></td></tr><tr><td>Mean ± SD</td><td>25.9 ± 6.1</td></tr><tr><td>Median (range)</td><td>24.4 (17.0 – 46.9)</td></tr><tr><td>BMI classes, n (%)</td><td></td></tr><tr><td>Underweight</td><td>10 (5.6)</td></tr><tr><td>Normal</td><td>85 (47.5)</td></tr><tr><td>Overweight</td><td>43 (24)</td></tr><tr><td>Obese</td><td>41 (22.9)</td></tr><tr><td><strong>PCOS phenotype, n (%)</strong></td><td></td></tr><tr><td>A</td><td>86 (48)</td></tr><tr><td>B</td><td>59 (33)</td></tr><tr><td>C</td><td>18 (10.1)</td></tr><tr><td>D</td><td>16 (8.9)</td></tr><tr><td><strong>Menstrual disorders, n (%)</strong></td><td></td></tr><tr><td>Spaniomenorrhea</td><td>94 (52.5)</td></tr><tr><td>Amenorrhea</td><td>67 (37.4)</td></tr><tr><td>Missing data</td><td>18 (10.1)</td></tr><tr><td><strong>Hyperandrogenism, n (%)</strong></td><td></td></tr><tr><td>Clinical</td><td>163 (91.1)</td></tr><tr><td>Biological</td><td>142 (79.3)</td></tr><tr><td>Biological</td><td>106 (59.2)</td></tr><tr><td><strong>PCOM, n (%)</strong></td><td></td></tr><tr><td>AFC</td><td></td></tr><tr><td>Mean ± SD</td><td>17.3 ± 9.2</td></tr><tr><td>Median (range)</td><td>15.5 (3.5 – 67.5)</td></tr><tr><td>Ovarian Surface, cm<sup>2</sup></td><td></td></tr><tr><td>Mean ± SD</td><td>5.5 ± 1.8</td></tr><tr><td>Median (range)</td><td>5.2 (2.0 – 10.6)</td></tr><tr><td><strong>Total testosterone, ULN</strong></td><td></td></tr><tr><td>Mean ± SD</td><td>1.01 ± 0.52</td></tr><tr><td>Median (range)</td><td>0.87 (0.10 – 2.86)</td></tr><tr><td><strong>17-OH-Progesterone, ULN</strong></td><td></td></tr><tr><td>Mean ± SD</td><td>0.57 ± 0.27</td></tr><tr><td>Median (range)</td><td>0.53 (0.14 – 1.6)</td></tr><tr><td><strong>Delta-4-Androstenedione, ng/ml</strong></td><td></td></tr><tr><td>Mean ± SD</td><td>2.44 ± 1.14</td></tr><tr><td>Median (range)</td><td>2.24 (0.32 – 7.50)</td></tr><tr><td><strong>DHEA-S, ULN</strong></td><td></td></tr><tr><td>Mean ± SD</td><td>0.83 ± 0.45</td></tr><tr><td>Median (range)</td><td>0.80 (0.06 – 2.94)</td></tr><tr><td><strong>Estradiol, ULN</strong></td><td></td></tr><tr><td>Mean ± SD</td><td>0.56 ± 0.52</td></tr><tr><td>Median (range)</td><td>0.45 (0.05 – 3.13)</td></tr><tr><td><strong>AMH, ng/ml</strong></td><td></td></tr><tr><td>Mean ± SD</td><td>6.63 ± 4.29</td></tr><tr><td>Median (range)</td><td>5.66 (0.67 – 22)</td></tr><tr><td><strong>Prolactin, ng/ml</strong></td><td></td></tr><tr><td>Mean ± SD</td><td>18.80 ± 16.78</td></tr><tr><td>Median (range)</td><td>14.80 (4.90 – 153.3)</td></tr><tr><td><strong>LH/FSH</strong></td><td></td></tr><tr><td>Mean ± SD</td><td>1.80 ± 1.20</td></tr><tr><td>Median (range)</td><td>1.58 (0.03 – 7.21)</td></tr></tbody></table>

AMH, Antimullerian Hormone; BMI, Body Mass Index; PCOM, Polycystic Ovarian Morphology; AFC, Antral Follicle Count; DHEA-S, Dehydroepiandrosterone sulfate; ULN, Upper Limit of Normal.

(Figures 3A, B p=0.297). Amongst the 21 patients with hPRL, PCOS phenotype A, B and C were found in 9 (42.8%), 9, (42.8%) and 3 patients (14.3%), respectively. There was no phenotype D.

At the biological level, PCOS/hPRL women had a lower mean AMH level (5.5 ± 4.2 ng/ml) as compared to women from the
<figure><img src="image_4.png" /><figcaption>**FIGURE 2** | BMI (kg/m²) according to PCOS phenotype.</figcaption></figure>

PCOS/nPRL cohort (6.76 ± 4.1 ng/ml), even though, this difference did not reach significance (p=0.190). We did not observe any correlation between the levels of AMH and PRL, neither in the whole cohort (r = -0.05, p = 0.5), nor in the PCOS/ hPRL group (r = 0.06, p = 0.8). We did not observe statistically significant differences in the ultrasonographic ovary characteristics of hPRL/PCOS as compared to nPRL/PCOS women (**Table 3**), and, moreover, we did not find specific ultrasonographic features related to hyperprolactinemia.

Finally, women of the PCOS/hPRL group had a trend for a less explosive response to the LHRH test (mean LH T30/LH T0 ratio = 6.4) as compared to women of the PCOS/nPRL group (mean LH T30/LH T0 ratio = 13.31) however without reaching statistical significance (p=0.671).

## Etiologies of hPRL

Five out of 21 (23.8%) women of the PCOS/hPRL group had a microprolactinoma. The mean diameter of the pituitary lesion was 4.4 ± 1.7 mm and the mean PRL value in this subgroup of women was 85 ± 45 ng/ml, significantly higher than the mean value in women with other causes of hPRL (35.7 ± 16.2 ng/ml, p < 0.001, **Figure 4A**). Based on the ROC curve, sensitivity/ specity of a PRL threshold of ≥ 60 ng/ml for the diagnosis of microprolactinoma as compared to other causes of hyperprolactinemia in PCOS women, was 100% (95% CI:56.5% -100%) and 93.7% (95% CI:71.7- 99.7%), respectively (**Figure 4B**, AUC = 0.962). All of these women were, subsequently, treated with dopamine agonist therapy which normalized PRL and decreased the size of the pituitary lesion. We did not identify patients with a macroprolactinoma or pituitary tumors responsible for a disconnection hPRL. Five patients (23.8%) had a macroprolactinemia, and one of them underwent a pituitary MRI before macroprolactinemia was ruled out. The MRI showed a 2.4 mm lesion which, after reexamining images, was uncertain. Four patients (19%) had an iatrogenic

hPRL (the use of medications was confirmed after a phone call). One patient (4.8%) had hPRL likely due to hypothyroidism after reexamination of her medical record, as her TSH reached 5.8 mIU/l on one measurement. However the link between hPRL and hypothyroidism is more obvious for TSH ≥ 7.5 mIU/l (15). Finally, 6 (28.6%) had an idiopathic hPRL, despite complete investigations (PRL chromatography, pituitary MRI, hypothyroidism, pregnancy, hPRL drugs) and a careful analysis of their medical files. In this subgroup, the mean PRL value was 33.4 ± 9.3 ng/ml.

A metoclopramide test was available in 14 patients with hPRL, including the 5 microprolactinomas. The test resulted in a stimulation of baseline PRL of less than 300% in all PRLomas, while it was above this cut-off in all the other etiologies (**Figure 4C**). In particular, the patient with the 2.4 mm pituitary lesion and macroprolactinemia, had a stimulation of her baseline PRL of 1218%.

In summary, our results suggest that performing metoclopramide test in PCOS women with hPRL, especially in those with value that remain below 60 ng/ml, could be a helpful tool for discussing the relevance of a pituitary MRI (**Figure 5**).

## DISCUSSION

The association of hyperprolactinemia (hPRL) and polycystic ovarian syndrome (PCOS) is not uncommon and raises essential questions for the therapeutic management of the patient. One can easily assume that information delivered to the patient, therapeutic outcome and follow-up strategy will substantially differ if a prolactin-secreting pituitary adenoma is diagnosed in addition to PCOS. In our study, confirmed hPRL was observed in 11.7% of PCOS women, however the reason for this hPRL remained unsolved for a quarter of them. Whether a pathophysiological link exists between PCOS and hPRL has
<table><caption>TABLE 3 | Univariate analysis between PCOS/nPRL cohort and PCOS/hPRL cohort.</caption><thead><tr><th>Characteristics</th><th>PCOS/nPRL (n = 158)</th><th>PCOS/hPRL (n = 21)</th><th>P value</th></tr></thead><tbody><tr><td><strong>Age, y</strong></td><td></td><td></td><td>P=0.977</td></tr><tr><td>Mean ± SD</td><td>23.8 ± 5.23</td><td>23.9 ± 5.44</td><td></td></tr><tr><td>Median (range)</td><td>22 (18 – 40)</td><td>23 (18 – 35)</td><td></td></tr><tr><td><strong>BMI, kg/m<sup>2</sup></strong></td><td></td><td></td><td>P=0.297</td></tr><tr><td>Mean ± SD</td><td>26.10 ± 6.33</td><td>23.98 ± 3.91</td><td></td></tr><tr><td>Median (range)</td><td>24.46 (17.00 – 46.88)</td><td>23.15 (17.47 – 35.25)</td><td></td></tr><tr><td><strong>PCOS phenotype, n (%)</strong></td><td></td><td></td><td>NS</td></tr><tr><td>A</td><td>77 (48.7)</td><td>9 (42.9)</td><td></td></tr><tr><td>B</td><td>50 (31.6)</td><td>9 (42.9)</td><td></td></tr><tr><td>C</td><td>15 (9.5)</td><td>3 (14.3)</td><td></td></tr><tr><td>D</td><td>16 (10.1)</td><td>0 (0)</td><td></td></tr><tr><td><strong>Menstrual disorders, n (%)</strong></td><td></td><td></td><td>NS</td></tr><tr><td>Spaniomenorrhea</td><td>84 (58.7)</td><td>10 (55.6)</td><td></td></tr><tr><td>Amenorrhea</td><td>59 (41.3)</td><td>8 (44.4)</td><td></td></tr><tr><td><strong>Hyperandrogeny, n (%)</strong></td><td></td><td></td><td>NS</td></tr><tr><td>Clinical</td><td>122 (85.9)</td><td>20 (95.2)</td><td></td></tr><tr><td>Biological</td><td>92 (65.7)</td><td>14 (66.7)</td><td></td></tr><tr><td><strong>PCOM, n (%)</strong></td><td></td><td></td><td>P=0.559</td></tr><tr><td>AFC</td><td></td><td></td><td>P=0.292</td></tr><tr><td>Mean ± SD</td><td>17.61 ± 9.23</td><td>15.19 ± 9.10</td><td></td></tr><tr><td>Median (range)</td><td>15.5 (3.5 – 67.5)</td><td>13.5 (5 – 40)</td><td></td></tr><tr><td>Ovarian Surface, cm<sup>2</sup></td><td></td><td></td><td>P=0.634</td></tr><tr><td>Mean ± SD</td><td>5.50 ± 1.86</td><td>5.04 ± 1.66</td><td></td></tr><tr><td>Median (range)</td><td>5.35 (2 – 10.61)</td><td>5.12 (2.16 – 7.63)</td><td></td></tr><tr><td><strong>Total testosterone, ULN</strong></td><td></td><td></td><td>P=0.268</td></tr><tr><td>Mean ± SD</td><td>1.03 ± 0.54</td><td>0.85 ± 0.37</td><td></td></tr><tr><td>Median (range)</td><td>0.88 (0.10 – 2.86)</td><td>0.76 (0.3 – 1.77)</td><td></td></tr><tr><td><strong>17-OH-Progesterone, ULN</strong></td><td></td><td></td><td>P=0.250</td></tr><tr><td>Mean ± SD</td><td>0.56 ± 0.27</td><td>0.60 ± 0.21</td><td></td></tr><tr><td>Median (range)</td><td>0.51 (0.14 – 1.60)</td><td>0.55 (0.28 – 1.14)</td><td></td></tr><tr><td><strong>Delta-4-Androstenedione, ng/ml</strong></td><td></td><td></td><td>P=0.144</td></tr><tr><td>Mean ± SD</td><td>2.40 ± 1.13</td><td>2.72 ± 1.21</td><td></td></tr><tr><td>Median (range)</td><td>2.20 (0.32 – 7.50)</td><td>2.80 (0.32 – 4.80)</td><td></td></tr><tr><td><strong>SDHEA, ULN</strong></td><td></td><td></td><td>P=0.243</td></tr><tr><td>Mean ± SD</td><td>0.82 ± 0.46</td><td>0.90 ± 0.28</td><td></td></tr><tr><td>Median (range)</td><td>0.79 (0.06 – 2.94)</td><td>0.84 (0.47 – 1.40)</td><td></td></tr><tr><td><strong>Estradiol, ULN</strong></td><td></td><td></td><td>P=0.852</td></tr><tr><td>Mean ± SD</td><td>0.54 ± 0.49</td><td>0.70 ± 0.78</td><td></td></tr><tr><td>Median (range)</td><td>0.46 (0.05 – 3.13)</td><td>0.41 (0.06 – 2.99)</td><td></td></tr><tr><td><strong>TSH, mUI/L</strong></td><td></td><td></td><td>P=0.826</td></tr><tr><td>Mean ± SD</td><td>2.26 ± 1.31</td><td>2.25 ± 1.22</td><td></td></tr><tr><td>Median (range)</td><td>1.95 (0.41 – 8.39)</td><td>2.10 (0.54 – 5.79)</td><td></td></tr><tr><td><strong>AMH, ng/ml</strong></td><td></td><td></td><td>P=0.190</td></tr><tr><td>Mean ± SD</td><td>6.76 ± 4.29</td><td>5.55 ± 4.27</td><td></td></tr><tr><td>Median (range)</td><td>5.80 (0.93 – 22)</td><td>5.12 (0.67 – 15.30)</td><td></td></tr><tr><td><strong>Prolactin, ng/ml</strong></td><td></td><td></td><td>P < 0.001</td></tr><tr><td>Mean ± SD</td><td>14.25 ± 4.96</td><td>53.03 ± 30.28</td><td></td></tr><tr><td>Median (range)</td><td>14.05 (4.9 – 23.9)</td><td>46.2 (24.7 – 153.3)</td><td></td></tr><tr><td><strong>LH/FSH TO</strong></td><td></td><td></td><td>P=0.655</td></tr><tr><td>Mean ± SD</td><td>13.31 ± 63.71</td><td>6.41 ± 4.56</td><td></td></tr><tr><td>Median (range)</td><td>4.42 (1.88 – 663)</td><td>4.49 (2.15 – 16.45)</td><td></td></tr></tbody></table>

AMH, Antimullerian Hormone; BMI, Body Mass Index; PCOM, Polycystic Ovarian Morphology; AFC, Antral Follicle Count; DHEA-S, Dehydroepiandrosterone sulfate; ULN, Upper Limit of Normal. Bold value means comparison reached significance. NS, Non significant.

been and is still widely discussed in the scientific community (16–18). The rapid evolution of knowledge about both PCOS and hPRL renders studies conducted before the 2000s, obsolete. Most of these studies were published before consensual diagnosis criteria of PCOS, while others used only one blood sample showing hPRL with no control, and finally, in another subset of studies, screening for macroprolactinemia was inconsistent. There are several mechanisms that have been proposed to

explain the increase of PRL in PCOS. One of them is the alteration of the dopamine turnover, responsible for an increase in PRL secretion, a deteriorated GnRH output and, eventually, an abnormal ovary function (19). Likewise, high levels of estrogens, similar to those found in PCOS, are known to stimulate the synthesis and secretion of PRL, as well as proliferation of lactotroph pituitary cells in animals (20–22). However, this relationship in humans is controversial (23–25)
<figure><img src="image_5.png" /><figcaption>**FIGURE 3** | Characteristics of weight in the two cohort of PCOS women. (A) mean BMI according to the presence of hPRL or not and (B) weight category according to the presence of hPRL or not. ns, non significant.</figcaption></figure>

<figure><img src="image_6.png" /><figcaption>**FIGURE 4** | (A) PRL levels according to the presence of a PRLeMA or another hPRL cause. The dashed line indicates a threshold of PRL of 60 ng/ml. (B) ROC curve assessing the statistic performances of basal PRL to distinguish PRLeMA from others causes of hPRL (C) Metoclopramide test results, with relative increase according to the presence of a PRLeMA or another hPRL cause. \*\*\*p < 0.001.</figcaption></figure>

and, our study does not support this hypothesis since estrogen levels did not differ significantly between PCOS women with and without hPRL. High PRL levels have been associated with alterations in steroidogenic enzyme activities, increased androgen production, insulin resistance, hirsutism and PCOS morphology (26, 27), all of the above being essential components of the PCOS phenotype.

None of the hormonal factors we collected significantly differed between PCOS/nPRL and PCOS/hPRL women. However, we hypothesized that hPRL patients could have a less pronounced phenotype of PCOS, as PRL is known to exert

a negative feedback action on the pulsatility of GnRH and the release of LH and FSH. We did not observe clinical or biochemical differences between the two populations of patients in our study with the exception of a higher proportion of obesity in the PCOS/nPRL group as compared to patients with hPRL. Should this be interpreted as a less pronounced metabolic syndrome phenotype is undetermined yet, however the metabolic aspect of PCOS continues to question experts of the field and leads to innovative pathophysiological links and statements, like the one recently published by Aversa et al. (28). Similarly, while not significant, we observed both a trend
<figure><img src="image_7.png" /><figcaption>**FIGURE 5** | Decisional algorithm for the etiology of hPRL in PCOS women.
*Pituitary MRI is advised in case of pituitary tumoral syndrome, dopamine agonist intention-to-treat or abnormalities of other pituitary hormones.</figcaption></figure>

for a less explosive response to the LHRH test in hPRL patients as compared to those with nPRL, and a lower AMH. Again, the negative feedback exerted by PRL at the pituitary level is a plausible explanation of this biological profile.

Another aspect of our study that must be emphasized is that more than a half of the patients with one single high value of PRL eventually had a normal value on a second sample. Because the context of the patient (i.e., oligo-anovulation, menstrual irregularities, desire for pregnancy) prompts clinicians to screen for an organic disease, it remains essential, in a first-step diagnosis procedure, to confirm hPRL on a second sample before any further investigations. The prevalence of prolactin-secreting pituitary adenoma (PRLoma) in our whole cohort was found to be 2.8%, slightly higher than the one reported in the literature (0.3 - 0.5%) (7). This difference makes sense, since all of our patients were selected with a systematic measure of prolactin (unlike in general population), and because the real prevalence of microprolactinoma in young women is likely to be underestimated (29). Our patients with PRLomas had a significantly higher value of PRL and all of them had a PRL value ≥ 60 ng/ml. A previous study suggested that a PRL threshold of 85.2 ng/ml could distinguish patients with PRLoma with 77% sensitivity and 100% specificity (30). Using this threshold in our study would have conducted to misdiagnose PRLoma in 4 out of 5 patients, underlying the fact that no optimal cutoff exists for the distinction of PRLomas and other causes of hPRL, and/or that cut-off values may differ depending on the characteristics of the assay used. In this setting, the use of dynamic tests, like metoclopramide injection, could be helpful.

The metoclopramide test has been developed in the 70's as a strong stimulator of PRL secretion (31) and is used to distinguish hPRL due to pituitary adenoma from other causes of hPRL (32), with a cut off of 300% being admitted as a limit of PRL stimulation beyond which hPRL is unlikely due to PRLoma (14). A previous study showed that the metoclopramide-induced stimulation of PRL secretion was preserved in PCOS women, with a ratio of stimulated/basal PRL up to 1000% (33). However, no previous work investigated the added value of the metoclopramide test in PCOS women with hPRL. As such, our study is the first to show that the metoclopramide test is helpful to distinguish hPRL secondary to microprolactinoma as compared to other causes of hPRL in PCOS women, and therefore could be an interesting tool for discussing the relevance of a pituitary MRI.

Our study has obvious limitations due to its retrospective nature. The monocentric enrollment of patients is naturally subjected to a bias of inclusion, even more because we included patients from endocrinology and medically assisted procreation departments. A high prevalence of PRLoma is, therefore, not that surprising since most patients complained of menstrual irregularities and/or oligo-anovulation, a bias that could slightly overestimate the real prevalence of PRLoma in PCOS women. Investigating the PRL level of PCOS women visiting a dermatologist for acne and/or hyperseborrhea, without menstrual disturbances, could be of interest in an upcoming study. The retrospective design of our study is another limitation as it can be a cause of missing data. Nonetheless, we also would like to highlight the strengths of our work. First, we accumulated data from many well-characterized women meeting the Rotterdam criteria to establish our reference population. Biological data were obtained through the intervention of the same paramedical team, treated in the same biological laboratory, interpreted by the same clinicians. Accordingly, we meticulously analyzed every medical file to enrol women that had a clear diagnosis of PCOS. We thus selected 179 out of 430 patients, and thereafter proceeded with the same methodology for hPRL patients. Those patients had at least 2 values of PRL above the limit of normal to be considered as being hyperprolactinemic. This arbitrary decision, which resulted from our aim to focus on "real" hPRL patients, allowed us to select 21 patients, and, at the same time, turned away 29 patients from this definition.

Overall, the prevalence of macroprolactinemia in our PCOS/hPRL population reached 24%, roughly similar to what is reported in the literature (34) confirming the fact that macroprolactinemia must be ruled out in priority, even in PCOS women, before proceeding with further investigations. A non-negligible subset of patients (28% in the PCOS/hPRL cohort) had an idiopathic hPRL based on our diagnostic criteria, and despite extensive investigations. Pituitary MRI was normal and mainly performed to rule out the possibility of a disconnection hPRL. These idiopathic cases had mild elevations of PRL and, importantly, all of them had a marked response (i.e., > 300% from baseline PRL) to the metoclopramide test, thus not in favor of picoprolactinomas (i.e., maximal size of adenoma
< 3 mm, usually not visualized on pituitary MRI). Whether a subtle interaction between PCOS pathophysiology and the mechanisms of PRL secretion occurs in these cases still needs to be deciphered.

In conclusion, our study shows that hyperprolactinemia is often present in lean PCOS women, occurring in almost 12% of cases. This suggests that a dedicated decisional algorithm to manage these patients may be helpful to treat patients with microprolactinomas and avoid unnecessary and costly diagnostic procedures in others (Figure 5).

## DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

## REFERENCES

1. Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. Criteria, Prevalence, and Phenotypes of Polycystic Ovary Syndrome. *Fertil Steril* (2016) 106:6-15. doi: 10.1016/j.FERTNSTERT.2016.05.003

2. March WA, Moore VM, Willson KJ, Phillips DIW, Norman RJ, Davies MJ. The Prevalence of Polycystic Ovary Syndrome in a Community Sample Assessed Under Contrasting Diagnostic Criteria. *Hum Reprod* (2010) 25:544-51. doi: 10.1093/HUMREP/DEP399

3. Wild R, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale H, Futterweit W, et al. Assessment of Cardiovascular Risk and Prevention of Cardiovascular Disease in Women With the Polycystic Ovary Syndrome: A Consensus Statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. *J Clin Endocrinol Metab* (2010) 95:2038-49. doi: 10.1210/JC.2009-2724

4. Alpañés M, Sanchón R, Martínez-García M, Martínez-Bermejo E, Escobar-Morreale H. Prevalence of Hyperprolactinaemia in Female Premenopausal Blood Donors. *Clin Endocrinol (Oxf)* (2013) 79:545-9. doi: 10.1111/CEN.12182

5. Vallette-Kasic S, Morange-Ramos I, Selim A, Gunz G, Morange S, Enjalbert A, et al. Macroprolactinemia Revisited: A Study on 106 Patients. *J Clin Endocrinol Metab* (2002) 87:581-8. doi: 10.1210/JCEM.87.2.8272

6. Kasum M, Pavićić-Baldani D, Stanić P, Orešković S, Sarić J, Blajić J, et al. Importance of Macroprolactinemia in Hyperprolactinemia. *Eur J Obstet Gynecol Reprod Biol* (2014) 183:28-32. doi: 10.1016/j.EJOGRB.2014.10.013

7. Molitch M. Diagnosis and Treatment of Pituitary Adenomas: A Review. *JAMA* (2017) 317:516-24. doi: 10.1001/JAMA.2016.19699

8. Carmina E, Rosato F, Maggiore M, Gagliano A, Indovina D, Janni A. Prolactin Secretion in Polycystic Ovary Syndrome (PCO): Correlation With the Steroid Pattern. *Acta Endocrinol (Copenh)* (1984) 105:99-104. doi: 10.1530/ACTA.0.1050099

9. Murdoch A, Dunlop W, Kendall-Taylor P. Studies of Prolactin Secretion in Polycystic Ovary Syndrome. *Clin Endocrinol (Oxf)* (1986) 24:165-75. doi: 10.1111/j.1365-2265.1986.TB00759.X

10. Casanueva F, Molitch M, Schlechte J, Abs R, Bonert V, Bronsteinn M, et al. Guidelines of the Pituitary Society for the Diagnosis and Management of Prolactinomas. *Clin Endocrinol (Oxf)* (2006) 65:265-73. doi: 10.1111/j.1365-2265.2006.02562.X

11. Teede HJ, Misso M, Costello M, Dokras A, Laven J, Moran L, et al. Recommendations From the International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. *Fertil Steril* (2018) 110(3):364-79. doi: 10.1016/j.fertnstert.2018.05.004

12. Dewailly D. Polycystic Ovary Syndrome. *J Gynecol Obstet Biol Reprod (Paris)* (2000) 29:298-301.

13. Espinós J, Vanrell C, Gich I, Urgell E, Calaf J. Pituitary Response Profile Following Metoclopramide Administration in Women With Different Forms

## ETHICS STATEMENT

Ethical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

## AUTHOR CONTRIBUTIONS

Conceptualization, CR and TC. Validation, BC, TB, and TC. Writing—original draft preparation, CR and TC. Writing—review and editing, CR, BC, MV, BF, NR, TB, and TC. Statistics, SF and NR. Supervision, TB and TC. All authors have read and agreed to the published version of the manuscript.

of Hyperprolactinemia. *Gynecol Endocrinol (Oxf)* (2017) 33:148-51. doi: 10.1080/09513590.2016.1222363

14. Escobar-Morreale HF. Defining PCOS: A Syndrome With An Intrinsic Heterogeneous Nature. In: Diamanti-Kandarakis E, editor. *Polycystic Ovary Syndrome*. Amsterdam: Elsevier (2022). pp. 3-13. doi: 10.1016/B978-0-12-823045-9.00012-2

15. Sharma LK, Sharma N, Gadpayle AK, Dutta D. Prevalence and Predictors of Hyperprolactinemia in Subclinical Hypothyroidism. *Eur J Intern Med* (2016) 35:106-10. doi: 10.1016/j.ejim.2016.07.012

16. Bracero N, Zacur H. Polycystic Ovary Syndrome and Hyperprolactinemia. *Obstet Gynecol Clin North Am* (2001) 28:77-84. doi: 10.1016/S0889-8545(05)70186-8

17. Robin G, Cattau-Jonard S, Young J, Dewailly D. Physiopathological Link Between Polycystic Ovary Syndrome and Hyperprolactinemia: Myth or Reality? *Gynecol Obstet Fertil* (2011) 39:141-5. doi: 10.1016/j.GYOBFE.2010.11.002

18. Delcour C, Robin G, Young J, Dewailly D. PCOS and Hyperprolactinemia: What do We Know in 2019? *Clin Med Insights Reprod Heal* (2019) 13:117955811987192. doi: 10.1177/1179558119871921

19. Plosker S, Marshall L, Martin M, Jaffe R. Opioid, Catecholamine, and Steroid Interaction in Prolactin and Gonadotropin Regulation. *Obstet Gynecol Surv* (1990) 45:441-53. doi: 10.1097/00006254-199007000-00003

20. Elias KA, Weiner RI. Direct Arterial Vascularization of Estrogen-Induced Prolactin-Secreting Anterior Pituitary Tumors. *Proc Natl Acad Sci USA* (1984) 81:4549. doi: 10.1073/PNAS.81.14.4549

21. Gersten B, Baker B. Local Action of Intrahypophyseal Implants of Estrogen as Revealed by Staining With Peroxidase-Labeled Antibody. *Am J Anat* (1970) 128:1-19. doi: 10.1002/AJA.1001280102

22. Sarkar D. Genesis of Prolactinomas: Studies Using Estrogen-Treated Animals. *Front Horm Res* (2006) 35:32-49. doi: 10.1159/000094307

23. Ehara Y, Siler TM, Yen SSC. Effects of Large Doses of Estrogen on Prolactin and Growth Hormone Release. *Am J Obstet Gynecol* (1976) 125:455-8. doi: 10.1016/0002-9378(76)90358-6

24. Ben-Jonathan N, LaPensee CR, LaPensee EW. What Can We Learn From Rodents About Prolactin in Humans? *Endocr Rev* (2008) 29:1-41. doi: 10.1210/ER.2007-0017

25. Christin-Maitre S, Delemer B, Touraine P, Young J. Prolactinoma and Estrogens: Pregnancy, Contraception and Hormonal Replacement Therapy. *Ann Endocrinol (Paris)* (2007) 68:106-12. doi: 10.1016/j.AND0.2007.03.008

26. Işık A, Gülekli B, Zorlu C, Ergin T, Gökmen O. Endocrinological and Clinical Analysis of Hyperprolactinemic Patients With and Without Ultrasonically Diagnosed Polycystic Ovarian Changes. *Gynecol Obstet Invest* (1997) 43:183-5. doi: 10.1159/000291850

27. Higuchi K, Nawata H, Maki T, Higashizima M, Kato K, Ibayashi H. Prolactin has a Direct Effect on Adrenal Androgen Secretion. *J Clin Endocrinol Metab* (1984) 59:714-8. doi: 10.1210/JCEM-59-4-714

28. Aversa A, La Vignera S, Rago R, Gambineri A, Nappi RE, Calogero AE, et al. Fundamental Concepts and Novel Aspects of Polycystic Ovarian Syndrome:
Expert Consensus Resolutions. *Front Endocrinol (Lausanne)* (2020) 11:516.
doi: 10.3389/fendo.2020.00516

29. Ezzat S, Asa S, Couldwell W, Barr C, Dodge W, Vance M, et al. The Prevalence of Pituitary Adenomas: A Systematic Review. *Cancer* (2004) 101:613-9.
doi: 10.1002/CNCR.20412

30. Kyritsi EM, Dimitriadis GK, Angelousi A, Mehta H, Shad A, Mytilinaiou M, et al. The Value of Prolactin in Predicting Prolactinoma in Hyperprolactinaemic Polycystic Ovarian Syndrome. *Eur J Clin Invest* (2018) 48:e12961. doi: 10.1111/ECI.12961

31. Sowers J, McCallum R JM, Hershman J, Carlson H, Sturdevant R, Meyer N. Comparison of Metoclopramide With Other Dynamic Tests of Prolactin Secretion. *J Clin Endocrinol Metab* (1976) 43:679-81. doi: 10.1210/JCEM-43-3-679

32. Healy D, Pepperell R, JStockdale J, Bremner W, Burger H. Pituitary Autonomy in Hyperprolactinemic Secondary Amenorrhea: Results of Hypothalamic-Pituitary Testing. *J Clin Endocrinol Metab* (1977) 44:809-19.
doi: 10.1210/JCEM-44-5-809

33. Mrozinska S, Przywara-Sikora A, Doroszewska K, Gałuszka-Bednarczyk A, Kiałka M, Guzik J, et al. Basal and Metoclopramide Induced Prolactin Secretion in Lean PCOS Women. *Neuroendocr Lett* (2019) 40(6):257-62.

34. Shimatsu A, Hattori N. Macroprolactinemia: Diagnostic, Clinical, and Pathogenic Significance. *Clin Dev Immunol* (2012) 2012:1-7. doi: 10.1155/2012/167132

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Rodier, Courbière, Fernandes, Vermalle, Florence, Resseguier, Brue and Cuny. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.